Baxter's New Look

Following its 1985 acquisition of American Hospital Supply, Baxter International reigned as one of the leading hospital suppliers, with a strong distribution component and an extremely broad product line. But though the strategy seemed right to appeal to a new kind of hospital customer, it did little to help Baxter grow as a corporation, and the company's stock hit a fallow period in the late 1980s and early 1990s. Beginning in the mid 1990s, Baxter embarked on a program to bring focus and discipline, in the process turning itself into a very different kind of business. By the end of the decade, it had shed virtually all of the businesses it acquired in the AHSC deal, re-focused on long-time efforts in dialysis and IV/medication delivery, and quietly built a huge biopharmaceutical business. Some questions linger for Baxter as it pursues a strategy with one foot in the medical device industry and one in biotech, most notably whether Baxter's R&D team can expertly maneuver in biopharmaceuticals. Still, the strategy seems to be working: Baxter is a leader in dialysis and IV solutions, has built a $2.5 billion biotech business, and has seen its market cap soar.

by David Cassak

One of the best-known names in the medical products industry, Baxter International Inc. may also be one of the most misunderstood. In the mid-1980s, shaken by the prospect that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business Strategy

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By 

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By 

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By 

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

Laying The Foundation And Overcoming Prerequisites To Establish AI Within Health Care

 
• By 

As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.

More from In Vivo

The 360 Degrees Of European Biotech Financing In 2025

 
• By 

Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.

Rising Leaders 2025: Pedro Valencia’s ADC Vision At AbbVie

 
• By 

From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.

Leaders At The Frontier: Conversations From SynBioBeta 2025

 
• By 

Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.